Abstract. We report the results of clinical studies carried out at six sites in Madagascar, between January and October 2006. The aims were (i) to update our knowledge of the burden of Plasmodium malariae infection and (ii) to assess the therapeutic efficacy of chloroquine for uncomplicated quartan malaria. Our findings confirm that P. malariae is the third leading cause of malaria, accounting for 1.1% of all malarial infections. They also demonstrate that chloroquine-currently recommended for the home management of presumed malaria in children under the age of five years and commonly used by adults-remains highly effective in patients with uncomplicated P. malariae infection.
Plasmodium malariae, one of the four species of Plasmodium affecting humans, is found in tropical and subtropical regions, often in sympatry with other Plasmodium species, as in Madagascar. Its reported prevalence varies from less than 4% to more than 20% in endemic regions. [1] [2] [3] [4] No accurate estimate of the prevalence of P. malariae infection worldwide is currently available, but it has been calculated that there are probably at least 60 million infections per year, based on the prevalence of P. falciparum 5, 6 and known underestimation of the prevalence of P. malariae. 7, 8 The clinical features associated with febrile bouts of P. malariae are generally milder than those caused by other species. 9 Fever displays quartan (4-day) periodicity, parasite density is usually considerably below 1000 parasites per ml of blood, and infection is rarely life-threatening in the absence of complications, such as nephrotic syndrome. [10] [11] [12] All four of the main malaria parasites affecting humans are present in Madagascar, a crossroads of African, Indo-Asian, Middle Eastern, and European civilizations. Malaria remains a serious public health problem (e.g., official data reported 1,227,632 cases of suspected malaria in 2005) and the leading cause of morbidity and mortality, especially in children under 5 years of age. [13] [14] [15] No recent data concerning the prevalence and chloroquine (CQ) sensitivity of P. malariae have been published. CQ is the antimalarial treatment recommended by the National Malaria Control Program (NMCP) for the home management of presumed malaria (HMM) in children under 5 years of age. P. malariae clearance from the blood is known to take longer than that of other species after chloroquine treatment 16 and two cases of resistance have been documented in south Sumatra, Indonesia. 17 Recent WHO guidelines for the testing of therapeutic efficacy have not yet been applied to P. malariae infection. We therefore report here the results of a clinical study carried out at six sites in 2006. The aims of this study were to: (i) update our knowledge of the burden of Plasmodium malariae infections and (ii) assess the therapeutic efficacy of CQ for uncomplicated quartan malaria.
This clinical study, approved by the National Ethics Committee of the Ministry of Health and Family Planning of Madagascar (N°102-SANPF-2006), was conducted in 2006, at six primary health centers and assessed the therapeutic efficacy of the main antimalarial drugs used in Madagascar. All patients with fever or a history of fever in the 48 h before their arrival at the health center were screened with the rapid diagnostic test (RDT) based on the detection of Plasmodiumspecific lactate dehydrogenase (pLDH) (OptiMAL-IT™, DiaMed AG © , Cressier sur Morat, Switzerland). Giemsastained thin and thick blood films were prepared for each patient with a positive RDT result. A microbiologist differentiated between the different Plasmodium species and parasitemia was assessed. Patients with histologically confirmed P. malariae infection were enrolled according to inclusion criteria adapted from the WHO guidelines (2001) 18 for P. vivax therapeutic efficacy tests. Informed consent was obtained from all adults and from at least one parent for minors. Patients were then treated with the standard chloroquine regimen of 25 mg/kg over 3 days and followed for 28 days. Clinical examination, including axillary temperature recording and the screening of thick and thin films, was carried out on days 0, 1, 2, 3, 7, 14, 21, and 28. On these days, capillary blood was spotted onto filter paper for PCR confirmation. Hemoglobin concentration was measured on days 0 and 28.
DNA was extracted from blood spots with Instagene® Matrix resin (BioRad©, Marnes la Coquette, France), according to the manufacturer's instructions. The parasite species was confirmed by real-time PCR, using species-specific primers as described by de Monbrison, 19 with a protocol adapted to the RotorGene® 3000 thermocycler (Corbett Life Science®, Sydney, Australia).
From January to October 2006, 6,692 patients were screened: 66.8% tested negative for malaria. Of the patients whose test results indicated the presence of malaria, 91.9% tested positive for P. falciparum and 8.1% for other Plasmodium species.
Microscopy results confirmed by species-specific real-time PCR showed that 86.9% of the patients infected with nonfalciparum species were infected with P. vivax and 13.1% were infected with P. malariae. None of the patients tested positive for P. ovale. Plasmodium malariae infection accounted for 0% (Ihosy) to 2.0% (Maevatanana) of all malaria cases, depending on the site considered (Figure 1 ).
Clinical and parasitological monitoring was complete for all (16 of 16) P. malariae-infected patients until day 28. There were six male and 10 female patients (62.5%), aged from 1 to 25 years (median 4.5), with a median weight of 10.5 kg (range 5-63). All patients had had fever during the past 48 hours and none declared having taken antimalarial drugs. Neither microscopy nor real-time PCR showed mixed infections (P. malariae with other species). The geometric mean of asexual parasite count was 947/L (range 250-14,000) at baseline.
None of the patients had detectable gametocytes on microscopy at day 0 or during the time of follow-up. Mean hemoglobin concentration was 9.1 g/dL on day 0, and the mean increase in hemoglobin concentration observed on day 28 (mean of individual increases in Hb) was 1.0 g/dL.
Fifteen patients successfully cleared P. malariae parasitemia after CQ treatment. One case was excluded on day 28 because P. falciparum parasites were detected on a blood smear (confirmed by real-time PCR). Microscopy showed parasite clearance before day 7 in all patients. However, realtime PCR showed parasites to be present in the blood, as described for diagnosis in one patient, and this patient displayed clearance between days 7 and 14 ( Figure 2) .
Our data confirm that P. malariae is the third leading cause of malaria in Madagascar after P. falciparum and P. vivax. No P. ovale parasites were observed due to the very low prevalence of this specie in Madagascar. 20 The prevalence of P. malariae, estimated at 1.1% of all malaria infections, was higher in the Western and the Central Highlands areas. This prevalence was most probably underestimated by using RDT based on pLDH detection for malaria diagnosis. According to our previous study, 21 its sensibility was estimated at 88.9-100% for parasitemias between 500 to 5000 non-P. falciparum parasites/L and at 50.0% when the number of parasites detected with microscopy falls below 100 parasites/L. Previous studies also reported a heterogeneous distribution of this specie according to season, transmission rate, and location: 1% of malaria infections in Analamiranga (western foothill area of the Highlands) 20 to 8.5% in Andasibe (eastern foothill area of the Highlands) and 12.3% at Sainte Marie (island east of the main island of Madagascar). 22, 23 Our study provides the first demonstration that CQ is highly effective against uncomplicated P. malariae infection in Madagascar. Three days of CQ treatment gave a clinical and parasitological cure rate of 100% by day 28 and a mean increase in hemoglobin concentration of 1 g/dl over the study period, whereas CQ is only effective in 55.6% of cases of uncomplicated P. falciparum malaria and in 89.7% of P. vivax malaria cases. 24 The NMCP has revised its treatment policy since December 2005, replacing CQ with artemisinin-based combination therapy (AQ+AS, artesunate plus amodiaquine), with the support of the Global Fund. 25 However, ACT treatment is used in only 31 of the 111 health districts in Eastern Madagascar. CQ remains the drug most widely available (distribution and financial criteria) and is the first drug used in most of areas in Madagascar, particularly in the prepackaged PaluStop form, sold at an affordable price (US $0.025), or as Ody Tazomoka, distributed free at primary public health facilities. 26 Obviously, with the progressive implementation of the artemisinin-based combination therapy, which is effective in treating malaria infections, 27 an approach that does not consider Plasmodium species seems to be the most suitable politic treatment at the primary healthcare facilities level in a country where material and human resources to perform a species-specific diagnosis are lacking.
In conclusion, our findings demonstrate that oral CQ, which is commonly used, remains highly effective in patients with uncomplicated P. malariae infection, the third leading cause of malaria in Madagascar.
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